News
CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and accompanying heart failure with preserved ejection fraction (HFpEF ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback